Myopia control and prevention: From lifestyle to low‐concentration atropine. The 2022 Josh Wallman Memorial Lecture

Abstract

AbstractThe purpose of this study was to explore the findings from the Hong Kong Children Eye Study and the Low Concentration Atropine for Myopia Progression (LAMP‐1) Study. The incidence of myopia among schoolchildren in Hong Kong more than doubled during the COVID‐19 pandemic, with outdoor time decreased significantly and screen time increased. The change in lifestyle during the COVID‐19 pandemic aggravated myopia development. Low‐concentration atropine (0.05%, 0.025% and 0.01%) is effective in reducing myopia progression with a concentration‐related response. This concentration‐dependent response was maintained throughout a 3‐year follow‐up period, and all low concentrations were well tolerated. An age‐dependent effect was observed in each treatment group with 0.05%, 0.025% and 0.01% atropine. Younger age was associated with a poor treatment response to low‐concentration atropine. Additionally, low‐concentration atropine induced choroidal thickening along a concentration‐dependent response throughout the treatment period. During the third year, continued atropine treatment achieved a better effect across all concentrations compared with the washout regimen. Stopping treatment at an older age and receiving lower concentration were associated with a smaller rebound effect. However, differences in the rebound effect were clinically small across all the three concentrations studied.